SyntheMed moves closer to $300m market
This article was originally published in Clinica
Edging a step closer to entering a $300m international market, SyntheMed's PMA application for its REPEL-CV adhesion barrier device, has been accepted by the US FDA.
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.